Steigerwald, Gordon & Koch Inc. Coherus Bio Sciences, Inc. Transaction History
Steigerwald, Gordon & Koch Inc.
- $977 Million
- Q3 2025
A detailed history of Steigerwald, Gordon & Koch Inc. transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Steigerwald, Gordon & Koch Inc. holds 1,000 shares of CHRS stock, worth $1,790. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,000Holding current value
$1,790% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CHRS
# of Institutions
122Shares Held
57.9MCall Options Held
89.3KPut Options Held
31K-
Black Rock Inc. New York, NY11.8MShares$21 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.6MShares$18.9 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA5.1MShares$9.12 Million0.22% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$5.43 Million0.09% of portfolio
-
Geode Capital Management, LLC Boston, MA2.68MShares$4.79 Million0.0% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $139M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...